Akst Lee M, Lee Walter, Discolo Christopher, Knott Daniel, Younes Abbas, Koltai Peter J
Department of Otolaryngology and Communicative Disorders, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Arch Otolaryngol Head Neck Surg. 2003 Aug;129(8):841-6. doi: 10.1001/archotol.129.8.841.
To evaluate a stepped-dose protocol for intralesional injection of cidofovir in children with recurrent respiratory papillomatosis (RRP).
Prospective, nonrandomized case series.
Tertiary care children's hospital.
Eleven children undergoing evaluation for RRP from June 1, 2000, through December 31, 2001.
Intralesional injection of cidofovir was performed after microlaryngoscopy and carbon dioxide laser treatment. Patients received 4 monthly injections at a concentration of 5 mg/mL and returned 1 month after the last injection for follow-up. Patients with recurrent or recalcitrant disease then started a series of 4 monthly injections at a concentration of 10 mg/mL.
Papilloma stage (0-3) documented at multiple subsites by means of serial microlaryngoscopy. We calculated a severity score by summing the scores at all affected subsites.
The severity score decreased in each of the 11 patients during the course of therapy, from a mean +/- SD of 13.7 +/- 6.0 at enrollment to 2.1 +/- 3.4 at 1-month follow-up. Six patients experienced complete resolution (stage 0) and 4 others had mild disease (stage, </=5) after 4 treatments at the 5-mg/mL concentration. Five patients with residual or recurrent RRP subsequently started a series of 4 cidofovir treatments at a concentration of 10 mg/mL, with a mixed response.
Intralesional injection of cidofovir seems to reduce the burden of disease in children with RRP. Patients with persistent or recurrent disease may benefit from an increased cidofovir concentration of 10 mg/mL, although some aggressive papillomatous disease remains refractory to cidofovir treatment.
评估病灶内注射西多福韦的逐步给药方案用于复发性呼吸道乳头状瘤病(RRP)患儿的疗效。
前瞻性、非随机病例系列研究。
三级护理儿童医院。
2000年6月1日至2001年12月31日期间接受RRP评估的11名儿童。
在显微喉镜检查和二氧化碳激光治疗后进行病灶内注射西多福韦。患者每月接受4次浓度为5mg/mL的注射,并在最后一次注射后1个月返回进行随访。复发或难治性疾病患者随后开始每月进行4次浓度为10mg/mL的注射。
通过系列显微喉镜检查记录多个亚部位的乳头状瘤分期(0-3期)。我们通过将所有受影响亚部位的评分相加来计算严重程度评分。
11例患者在治疗过程中严重程度评分均下降,从入组时的平均±标准差13.7±6.0降至1个月随访时的2.1±3.4。6例患者在接受5mg/mL浓度的4次治疗后实现完全缓解(0期),另外4例患者病情较轻(分期≤5期)。5例残留或复发性RRP患者随后开始接受4次浓度为10mg/mL的西多福韦治疗,反应不一。
病灶内注射西多福韦似乎可减轻RRP患儿的疾病负担。持续或复发疾病的患者可能受益于将西多福韦浓度提高至10mg/mL,尽管一些侵袭性乳头状瘤病对西多福韦治疗仍有耐药性。